Listeria monocytogenes as an alternative vaccine vector for HIV

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 3, 2000, Pages 151-162

  Mata, Marielena ^a   Paterson, Yvonne ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HIV vaccine; Listeria monocytogenes; Vaccine vector

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; GAG PROTEIN; HEMOLYSIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LISTERIOLYSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; METALLOPROTEINASE; PHOSPHOLIPASE C;

CLINICAL TRIAL; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LISTERIA MONOCYTOGENES; NONHUMAN; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MICE;

EID: 0033852259     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. ADAMS, D. O. and HAMILTON T. A. (1984): The cell biology of macrophage activation. Ann. Rev. Immunol., 2, 283-318.
2. ALFORD C. E., AMARAL E. and CAMPBELL P. A. (1990): Listericidal activity of human neutrophil cathepsin G. J. Gen. Microbiol., 136, 997-1000.
3. ALVAREZ-DOMINGUEZ C. E., CARRASCO-MARIN E. and LEYVA-COBIAN F. (1993): Role of complement component Clq in phagocytosis of Listeria monocytogenes by murine macrophage-like cell lines. Infect. Immun., 61, 3664-3672.
4. ANDERSSON S., MAKITALO B., THORSTENSSON R., FRANCHINI G., TARTAGLIA J., LIMBACH K., PAOLETTI E., PUTKONEN P. and BIBERFELD G. (1996): Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J. Infect. Dis., 174, 977-985.
5. ARMSTRONG D. (1985): Listeria monocytogenes. In MANDELL G. L., DOUGLAS R. G. and BENNETT J. E. (eds.): Principles and practice of infectious diseases, second edition. J Wiley and Sons, Inc., New York, 1177-1182.
6. BARRE-SINOUSSI F., CHERMANN J. C., REY F., NUGEYRE M. T., CHAMARET S., GRUEST J., DAUGUET C., AXLER-BLIN C., VEZINET-BRUN F., ROUZIOUX C., ROZENBAUM W. and MONTAGNIER L. (1983): Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220, 868-871.
7. BECKER Y. (1994): HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses - a review. Virus Genes, 8, 249-270.
8. BECKERMAN K. P., ROGERS H. W., CORBETT J. A., SCHREIBER R. D., MCDANIEL M. L. and UNANUE E. R. (1993): Release of nitric oxide during the T cell-independent pathway of macrophage activation. J. Immunol., 150, 888-895.
9. BELYAKOV I. M., Moss B., STROBER W. and BERZOFSKY J. A. (1999): Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA, 96, 4512-4517.
10. BERCHE P., GAILLARD J. and SANSONETTI P. J. (1987): Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. J. Immunol., 138, 2266-2271.
11. BERZOFSKY J. A. and BERKOWER I. J. (1995): Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995. AIDS, 9 (suppl. A), S143-157.
12. BOLOGNESI D. P. (1996): Overview of HIV vaccine development. Antibiot. Chemother., 48, 63-67.
13. BOYER J. D., UGEN K. E., WANG B., AGADJANYAN M., GILBERT L., BAGARAZZI M. L., CHATTERGOON M., FROST P., JAVADIAN A., WILLIAMS W. V., REFAELI Y., CICCARELLI R. B., MC CALLUS D., CONEY L. and WEINER D. B. (1997): Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med., 3, 526-532.
14. BROOME C. (1993): Listeriosis: can we prevent it? ASM News, 59, 444-446.
15. + T cells requires secretion of hemolysin and intracellular bacterial growth. J. Immunol., 145, 3540-3546.
16. BUGE S. L., RICHARDSON E., ALIPANAH S., MARKHAM P., CHENG S., KALYAN N., MILLER C. J., LUBECK M., UDEM S., ELDRIDGE J. and ROBERT-GUROFF M. (1997): An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol., 71, 8531-8541.
17. CAMILLI A., TILNEY L. G. and PORTNOY D. A. (1993): Dual roles of plcA in Listeria monocytogenes pathogenesis. Mol. Microbiol., 8, 143-157.
18. CASARES S., INABA K., BRUMEANU T. D., STEINMAN R. M. and BONA C. A. (1997): Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med., 186, 1481-1486.
19. CLERICI M. and SHEARER G. M. (1993): A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today, 14, 107-111.
20. CONLAN J. W. and NORTH R. J. (1992): Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect. Immun., 60, 5164-5171.
21. CONLAN J. W. and NORTH R. J. (1993): Neutrophil-mediated lysis of infected hepatocytes. ASM News, 59, 563-567.
22. COONEY E. L., COLLIER A. C., GREENBERG P. D., COOMBS R. W., ZARLING J., ARDITTI D. E., HUFFMAN M. C., HU S. L. and COREY L. (1991): Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet, 337, 567-572.
23. CORR M., LEE D. J., CARSON D. A. and TIGHE H. (1996): Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med., 184, 1555-1560.
24. COSSART P., VINCENTE M. F., MENGAUD J., BAQUERO F., PEREZ-DIAZ J. C. and BERCHE P. (1989): Listeriolysin O is essential for virulence of Listeria monocytogenes: direct evidence obtained by gene complementation. Infect. Immun., 57, 3629-3636.
25. CURRAN J. W., JAFFE H. W., HARDY A. M., MORGAN W. M., SELIK R. M. and DONDERO T. J. (1988): Epidemiology of HIV infection and AIDS in the United States. Science, 239, 610-616.
26. CZUPRYNSKI C. J. and HAAK-FRENDSCHO M. (1997): Non-specific resistance mechanisms to listeriosis: implications for experimental and naturally occurring infection. Immunol. Rev., 158, 47-56.
27. CZUPRYNSKI C. J., HENSON P. M. and CAMPBELL P. A. (1984): Killing of Listeria monocytogenes by inflammatory neutrophils and mononuclear phagocytes from immune and nonimmune mice. J. Leukoc. Biol., 35, 193-208.
28. DANIEL M. D., KIRCHHOFF F., CZAJAK S. C., SEHGAL P. K. and DESROSIERS R. C. (1992): Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science, 258, 1938-1941.
29. DA SILVA L. J., RESENDE M. R., DE ABREU W. B., AOKI F. H., BOCATTO R. B., BRANCHINNI M. L., GONCALES F. L. JR., DE LIMA J. N., VON NOWAKONSKI A. and PAPAIORDANOU A. (1992): Listeriosis and AIDS: case report and literature review. Rev. Inst. Med. Trop. Sao Paulo, 34, 475-478.
30. DAUGELAT S., LADEL C. H., SCHOEL B. and KAUFMANN S. H. E. (1994): Antigen-specific T cell responses during primary and secondary L. monocytogenes infection. Infect. Immun., 62, 1881-1888.
31. DEACON N. J., TSYKIN A., SOLOMON A., SMITH K., LUDFORD-MENTING M., HOOKER D. J., MCPHEE D. A., GREENWAY A. L., ELLETT A.,CHATFIELD C. et al. (1995): Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science, 270, 988-991.
32. DECKER C. F., SIMON G. L., DIGIOIA R. A. and TUAZON C. U. (1991): Listeria monocytogenes infections in patients with AIDS: report of five cases and review. Rev. Infect. Dis., 13, 413-417.
33. Department of Health and Human Services/Henry J. Kaiser Family Foundation Panel on clinical practices for treatment of HIV infection (1998): Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR, 47, 43-82.
34. DI FABIO S., MEDAGLINI D., RUSH C. M., CORRIAS F., PANZINI G. L., PACE M., VERANI P., POZZI G. and TITTI F. (1998): Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine, 16, 485-492.
35. DING A. H., NATHAN C. F. and STUEHR D. J. (1988): Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J. Immunol., 141, 2407-2412.
36. DRAMSI S., KOCKS C., FORESTIER C. and COSSART P. (1993): Internalin-mediated invasion of epithelial cells by Listeria monocytogenes is regulated by the bacterial growth state, temperature and the pleiotropic activator prfA. Mol. Microbiol., 9, 931-941.
37. DREVETS D. A. and CAMPBELL P. A. (1991): Roles of complement and complement receptor type 3 in phagocytosis of Listeria monocytogenes by inflammatory mouse peritoneal macrophages. Infect. Immun., 59, 2645-2652.
38. DUNN P. L. and NORTH R. J. (1991): Early gamma interferon production by natural killer cells is important in defense against murine listeriosis Infect. Immun., 15, 382-385.
39. DUNNE D. W., RESNICK D., GREENBERG J., KRIEGER M. and JOINER K. A. (1994): The type I macrophage scavenger receptor binds to Gram-positive bacteria and recognizes lipoteichoic acid. Proc. Natl. Acad. Sci. USA, 91, 1863-1867.
40. EGAN M. A., PAVLAT W. A., TARTAGLIA J., PAOLETTI E. WEINHOLD K. J., CLEMENTS M. L. and SILICIANO R. F. (1995): Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J. Infect. Dis. 171, 1623-1627.
41. ESPARZA J., HEYWARD W. L. and OSMANOV S. (1996): HIV vaccine development: from basic research to human trials. AIDS, 10 (suppl. A), S123-132.
42. FAUCI A. S. (1993): Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science, 262, 1011-1018.
43. FERRARI G., BEREND C., OTTINGER J., DODGE R., BARTLETT J., TOSO J., MOODY D., TARTAGLIA J., COX W. I., PAOLETTI E. and WEINHOLD K. J. (1997): Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood, 90, 2406-2416.
44. FERRARI G., HUMPHREY W., MCELRATH M. J., EXCLER J. L., DULIEGE A. M., CLEMENTS M. L., COREY L. C., BOLOGNESI D. P. and WEINHOLD K. J. (1997): Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfectcd volunteers. Proc. Natl. Acad. Sci. USA, 94, 1396-1401.
45. FLEURY B., JANVIER G., PIALOUX G., BUSEYNE F., ROBERTSON M. N., TARTAGLIA J., PAOLETTI E., KIENY M. P., EXCLER J. L. and RIVIERE Y. (1996): Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp 160. J. Infect. Dis., 174, 734-738.
46. FRANKEL F. R., HEGDE S., LIEBERMAN J. and PATERSON Y. (1995): Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J. Immunol., 155, 4775-4782.
47. FREITAG N. E., YONGMAN P. and PORTNOY D. A. (1992): Transcriptional activation of the Listeria monocytogenes hemolysin gene in Bacillus subtilis. J. Bacteriol., 174, 1293-1298.
48. FULLER D. H., MURPHEY-CORB M., BARNETT S., STEIMER K. and HAYNES J. R. (1997): Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine, 15, 924-926.
49. FULLER D. H., MURPHEY-CORB M., CLEMENTS J., BARNETT S. and HAYNES J. R. (1996): Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J. Med. Primatol., 25, 236-241.
50. FULLER D. H., SIMPSON L., COLE K. S., CLEMENTS J. E., PANICALI D. L., MONTELARO R. C., MURPHEY-CORB M. and HAYNES J. R. (1997): Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol. Cell. Biol., 75, 389-396.
51. GAILLARD J. L., BERCHE P., FREHEL C., GOUIN E. andCOSSART P. (1991): Entry of L. monocytogenes into cells is mediated by Internalin, a repeat protein reminiscent of surface antigens from Gram-positive Cocci. Cell, 65, 1127-1141.
52. GAILLARD J. L., BERCHE P., MOUNIER J., RICHARD S. and SANSONETTI P. (1987): In vitro model of penetration and intracellular growth of Listeria monocytogenes in the human enterocytelike cell line Caco-2. Infect. Immun., 55, 2822-2829.
53. GALEA P., LE CONTEL C., COUTTON C. and CHERMANN J. C. (1999): Rationale for a vaccine using cellular-derived epitope presented by HIV isolates. Vaccine, 17, 1700-1705.
54. GALLO R. C., SALAHUDDIN S. Z., POPOVIC M., SHEARER G. M., KAPLAN M., HAYNES B. F., PALKER T. J., REDFIELD R., OLESKE J., SAFAI B., WHITE G., FOSTER P. and MARKHAM P. D. (1984): Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 224, 500-503.
55. GEGINAT G., LALIC M., KRETSCHMAR M., GOEBEL W., HOF H., PALM D. and BUBERT A. (1998): Th1 cells specific for a secreted protein of Listeria monocytogenes are protective in vivo. J. Immunol., 160, 6046-6055.
56. GELLIN B. G. and BROOME C. V. (1989): Listeriosis. JAMA, 261, 1313-1320.
57. + T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int. Immunol., 7, 797-805.
58. GORSE G. J., FREY S. E., PATEL G., NEWMAN F. K. and BELSHE R. B. (1994): Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine, 12, 912-918.
59. GORSE G. J., ROGERS J. H., PERRY J. E., NEWMAN F. K., FREY S. E., PATEL G. B. and BELSHE R. B. (1995): HIV-1 recombinant gp 160 vaccine induced antibodies in serum and saliva. Vaccine, 13, 209-214.
60. GRAHAM B. S., BELSHE R. B., CLEMENTS M. L., DOLIN R., COREY L., WRIGHT P. F., GORSE G. J., MIDTHUN K., KEEFER M. C., ROBERTS N. J. JR. et al. (1992): Vaccination of vaccinianaive adults with human immunodeficiency virus type 1 gp 160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J. Infect. Dis. 166, 244-252.
61. GRAHAM B S., GORSE G. J., SCHWARTZ D. H., KEEFER M. C., MCELRATH M. J., MATTHEWS T. J., WRIGHT P. F., BELSHE R. B., CLEMENTS M. L., DOLIN R. et al. (1994): Determinants of antibody response after recombinant gp 160 boosting in vaccinianaive volunteers primed with gp 160-recombinant vaccinia virus. J. Infect. Dis., 170, 782-786.
62. + T cells. Infect. Immun., 63, 2288-2294.
63. HART M. K., PALKER T. J. and HAYNES B. F. (1995): Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Pharm. Biotechnol., 6, 821-845.
64. HARTY J. T. and PAMER E. G. (1995): CD8 T lymphocytes specific for the secreted p60 antigen protect against Listeria monocytogenes infection. J. Immunol. 154, 4642-4650.
65. HARTY J. T., SCHREIBER R. D. and BEVAN M. J. (1992): CD8 T cells can protect against an intracellular bacterium in an interferon γ-independent fashion. Proc. Natl. Acad. Sci. USA, 89, 11612-11616.
66. HAYNES B. F. (1996): HIV vaccines: where we are and where we are going. Lancet, 348, 933-937.
67. HlROMATSU K., YOSHIKAI Y., MATSUZAKI G., OHGA S., MURAMORI K., MATSUMOTO K., BLUESTONE J. A. and NOMOTO K. (1992): A protective role of γ/δ T cells in primary infection with Listeria monocytogenes in mice. J. Exp. Med., 175, 49-56.
68. HU S. L., ABRAMS K., BARBER G. N., MORAN P., ZARLING J. M., LANGLOIS A. J., KULLER L., MORTON W. R. and BENVENISTE R. E. (1992): Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp 160. Science, 255, 456-459.
69. IKONOMIDIS G., PATERSON Y., KOS F. and PORTNOY D. (1994): Delivery of a viral antigen to the class I. Processing and presentation pathway by L. monocytogenes. J. Exp. Med., 180, 2209-2218.
70. IKONOMIDIS G., PORTNOY D. A., GERHARD W. and PATERSON Y. (1997): Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines. Vaccines, 15, 433-440.
71. IWASAKI A., TORRES C. A., OHASHI P. S., ROBINSON H. L. and BARBER B. H. (1997): The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol., 159, 11-14.
72. JACOBS J. L. and MURRAY H. W. (1986): Why is Listeria monocytogenes not a pathogen in the acquired immunodeficiency syndrome? Arch. Intern. Med., 146, 1299-1300.
73. JURADO R. L., FARLEY M. M., PEREIRA E., HARVEY R. C., SCHUCHAT A., WENGER J. D. and STEPHENS D. S. (1993): Increased risk of meningitis and bacteremia due to Listeria monocytogenes in patients with human immunodeficiency virus infection. Clin. Infect. Dis., 17, 224-227.
74. + T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur. J. Immunol., 24, 3068-3072.
75. KAGI D., LEDERMANN B., BURKI K., SEILER P., ODERMATT B., OLSEN K. J., PODACK E. R., ZINKERNAGEL R. M. and HENGARTNER H. (1994): Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature, 369, 31-37.
76. KELLEHER A. D., EMERY S., CUNNINGHAM P., DUNCOMBE C., CARR A., GOLDING H., FORDE S., HUDSON J., ROGGENSACK M., FORREST B. D. and COOPER D. A. (1997): Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res. Hum. Retroviruses, 13, 29-32.
77. KIRCHHOFF F., GREENOUGH T. C., BRETTLER D. B., SULLIVAN J. L. and DESROSIERS R. C. (1995): Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med., 332, 228-232.
78. KOCKS C., GOUIN E., TABOURET M., BERCHE P., OHAYON H. and COSSART P. (1992): L monocytogenes-induced actin assembly requires the actA gene product, a surface protein. Cell, 68, 521-531.
79. KOJIMA H., SHINOHARA N., HANAOKA S., SOMEYA-SHIROTA Y., TAKAGAKI Y., OHNO H., SAITO T., KATAYAMA T., YAGITA H., OKUMURA K. et al. (1994): Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity, 1, 357-364.
80. KRIEG A. M., YI A. K., MATSON S., WALDSCHMIDT T. J., BISHOP G. A., TEASDALE R., KORETZKY G. A. and KLINMAN D. M. (1995): CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546-549.
81. LANE F. C. and UNANUE E. R. (1972): Requirement of thymus (T) lymphocytes for resistance to listeriosis. J. Exp. Med., 135, 1104-1112.
82. LEARMONT J., TINDALL B., EVANS L., CUNNINGHAM A., CUNNINGHAM P., WELLS J., PENNY R., KALDOR J. and COOPER D. A. (1992): Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet, 340, 863-867.
83. LEIMEISTER-WACHTER M., HAFFNER C., DOMANN E., GOEBEL W. and CHAKRABORTY T. (1990): Identification of a gene that positively regulates expression of listeriolysin, the major virulence factor of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA, 87, 8336-8340.
84. LETVIN N. L. (1998): Progress in the development of an HIV-1 vaccine. Science, 280, 1875-1880.
85. LEVY J. A., HOFFMAN A. D., KRAMER S. M., LANDIS J. A., SHIMABUKURO J. M. and OSHIRO L. S. (1984): Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science, 225, 840-842.
86. LOWIN B., BEERMANN F., SCHMIDT A. and TSCHOPP J. (1994): A null mutation in the perforin gene impairs cytolytic T lymphocyte-and natural killer cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA, 91, 11571-11575.
87. MACKANESS G. B. (1962): Cellular resistance to infection. J. Exp. Med., 116, 381-406.
88. MACKANESS G. B. (1964): The immunological basis of acquired cellular resistance. J. Exp. Med., 120, 105-120.
89. MACKANESS G. B. (1969): The influence of immunologically committed lymphoid cells on macrophage activity in vitro. J. Exp. Med., 129, 973-992.
90. MARQUIS H., DOSHI V. and PORTNOY D. A. (1995): The broadrange phospholipase C and the metalloprotease mediate listeriolysin O independent escape of Listeria monocytogenes from a primary vacuole in human epithelial cells. Infect. Immun., 63, 4531-4534.
91. MATA M. and PATERSON Y. (1999): Th1 T cell responses to HIV-1 Gag protein delivered by a L. monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J. Immunol., 163, 1449-1456.
92. d through interactions between a glutamine at P3 and pocket D. J. Immunol., 161, 2985-2993.
93. MENGAUD J., DRAMSI S., GOUIN E., VAZQUEZ-BOLAND J. A., MILON G. and COSSART P. (1991): Pleiotropic control of Listeria monocytogenes virulence factors by a gene that is auto-regulated. Mol. Microbiol., 5, 2273-2283.
94. MENGAUD J., OHAYON H., GOUNON P., MEGE R. and COSSART P. (1996): E-cadherin is the receptor for internalin, a surface protein required for entry of L. monocytogenes into epithelial cells. Cell, 84, 923-932.
95. MIELKE M. E., EHLERS S. and HAHN H. (1988): T-cell subsets in delayed-type hypersensitivity, protection and granuloma formation in primary and secondary Listeria infection in mice: Superior role of Lyt-2+ cells in acquired immunity. Infect. Immun., 56, 1920-1925.
96. MOMBAERTS P., ARNOLDI J., RUSS F., TONEGAWA S. and KAUFMANN S. H. E. (1993): Different roles of αβ and γδ T cells in immunity against an intracellular bacterial pathogen. Nature, 365, 53-56.
97. MUNK M. E. and KAUFMANN S. H. E. (1988): Listeria monocytogenes reactive T lymphocytes in healthy individuals. Microb. Pathog., 5, 49-54.
98. MURTHY K., K., COBB E. K., ROUSE S. R., MCCLURRE H. M., PAYNE J. S., SALAS M. T. and MICHALEK G. R. (1988): Active and passive immunization against HIV type 1 infection in chimpanzees. AIDS Res. Hum. Retroviruses, 14 (suppl. 3), S271-276.
99. NAGATA S. (1997): Apoptosis by death factor. Cell, 88, 355-365.
100. NEWBORG M. F. and NORTH R. J. (1980): On the mechanism of T cell independant anti-Listeria resistance in nude mice. J. Immunol., 124, 571-576.
101. PAMER E. G. (1993): Cellular immunity to intracellular bacteria. Curr. Opin. Immunol., 5, 492-496.
102. PAN Z.-K., IKONOMIDIS G., LAZENBY A., PARDOLL D. and PATERSON Y. (1995): A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour challenge and causes regression of established tumours. Nat. Med., 1, 471-477.
103. PAN Z.-K., IKONOMIDIS G., PARDOLL D. and PATERSON Y. (1995): Regression of established cancer mediated by the oral delivery of a recombinant Listeria monocytogenes vaccine expressing a model tumour antigen. Cancer Res., 55, 4776-4779.
104. PAN Z.-K., WEISKIRCH L. and PATERSON Y. (1999): Immunotherapy of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. (in press).
105. PARDOLL D. M. (1996): Cancer vaccines: A road map for the next decade. Curr. Opin. Immunol., 8, 619-621.
106. PERALES M. A., SCHWARTZ D. H., FABRY J. A. and LIEBERMAN J. (1995): A vaccinia-gp 160-based vaccine but not a gp 160 protein vaccine elicits anti-gp 160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 10, 27-35.
107. PINCUS S. H., MESSER K. G., COLE R., IRELAND R., VANCOTT T. C., PINTER A., SCHWARTZ D. H., GRAHAM B. S. and GORSE G. J. (1997): Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol., 158, 3511-3520.
108. PORTNOY D. A. (1992): Innate immunity to a facultative intracellular bacterial pathogen. Curr. Opin. Immunol., 4, 20-24.
109. PORTNOY D. A. (1994): Cellular biology of Listeria monocytogenes infection. In MILLER V. L., KAPER J. B., PORTNOY D. A. and ISBERG R. R. (eds.): Molecular genetics of bacterial pathogenesis. American Society for Microbiology, Washington, DC, 279-293.
110. PORTNOY D. A., JACKS P. S. and HINRICHS D. J. (1988): Role of hemolysin for the intracellular growth of Listeria monocytogenes. J. Exp. Med., 167, 1459-1471.
111. RENCHER S. D., LOCKEY T. D., SRINIVAS R. V., OWENS R. J. and HURWITZ J. L. (1997): Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine, 15, 265-272.
112. RIDA W. N. (1996): Assessing the effect of HIV vaccination on infectiousness. Stat. Med., 15, 2393-2404; discussion 2405-2312.
113. ROBERTS A. D., ORDWAY D. J. and ORME I. M. (1993): Listeria monocytogenes infection in β2 microglobulin-deficient mice. Infect. Immun., 61, 1113-1116.
114. RUPRECHT R. M., BABA T. W. and LISKA V. (1996): Attenuated HIV vaccine: caveats. Science, 271, 1790-1792.
115. SALK A., BRETSCHER P. A., SALK P. L., CLERICI M. and SHEARER G. (1993): A strategy for prophylactic vaccination against HIV. Science, 260, 1270-1278.
116. SCHAFER R., PORTNOY D. A., BRASSELL S. A. and PATERSON Y. (1992): Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. Immunol., 149, 53-59.
117. SCHLECH W. F. D., LAVIGNE P. M., BORTOLUSSI R. A., ALLEN A. C., HALDANE E. V., WORT A. J., HIGHTOWER A. W., JOHNSON S. E., KING S. H., NICHOLLS E. S. and BROOME C. V. (1983): Epidemic listeriosis - evidence for transmission by food. N. Engl. J. Med., 308, 203-206.
118. SHEN H., MILLER J. F., FAN X., KOLWYCK D., AHMED R. and HARTY J. T. (1998): Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell, 92, 535-545.
119. SHEN H., SLIFKA M. K., MATLOUBIAN M., JENSEN E. R., AHMED R. and MILLER J. F. (1995): Recombinant Listeria monocytoenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Natl. Acad. Sci. USA, 92, 3987-3991.
120. SLIFKA M. K., SHEN H., MATLOUBIAN M., JENSEN E. R., MILLER J. F. and AHMED R. (1996): Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes. J. Virol., 70, 2902-2910.
121. STEGER K. K. and PAUZA C. D. (1997): Immunization of Macaca mulatta with aroA attenuated Salmonella typhimurium expressing the SIVp27 antigen. J. Med. Primatol., 26, 44-50.
122. TILNEY L. G., CONNELLY P. S. and PORTNOY D. A. (1990): The nucleation of actin filaments by the bacterial intracellular pathogen, Listeria monocytogenes. J. Cell. Biol., 111, 2979-2988.
123. TILNEY L. G. and PORTNOY D. A. (1989): Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J. Cell. Biol., 109, 1597-1608.
124. TRIPP C. S., WOLF S. F. and UNANUE E. R. (1993): Interleukin 12 and tumor necrosis factor αa are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl. Acad. Sci. USA, 90, 3725-3729.
125. UGEN K. E., NYLAND S. B., BOYER J. D., VIDAL. C., LERA L., RASHEID S., CHATTERGOON M., BAGARAZZI M. L., CICCARELLI R., HIGGINS T., BAINE Y., GINSBERG R., MACGREGOR R. R. and WEINER D. B. (1998): DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine, 16, 1818-1821.
126. ULMER J. B., DECK R. R., DEWITT C. M., DONNHLY J. I. and LIU M. A. (1996): Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology, 89, 59-67.
127. WALSH C. M., MATLOUBIAN M., LIU C. C., UEDA R., KURAHARA C. G., CHRISTENSEN J. L., HUANG M. T., YOUNGJ. D., AHMED R. and CLARK W. R. (1944): Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. USA, 91, 10854-10858.
128. World Health Organization (1998): World Health Organization AIDS epidemic update: December 1998.
129. World Health Organization (1999): The World Health Report - Making a difference.
130. WYAND M. S., MANSON K. H., LACKNER A. A. and DESROSIERS R. C. (1997): Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat. Med., 3, 32-36.